Trans-Pacific Partnership agreement could limit access to affordable medicines, says academic
Author: Brook K. Baker, Northeastern Univ. School of Law, on PLOS Medicine (USA), Published on: 5 April 2016
"Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere", 8 Mar 2016
A new Pacific-Rim trade agreement threatens future access to affordable medicines in the United States and abroad...One of the most contentious chapters in the TPP is the Intellectual Property (IP) Chapter , whose patent, undisclosed-test-or-other-data, and enforcement provisions could dramatically affect access to affordable medicines. Equally contentious is the Investment Chapter , in which protection of IP-related investments and investor-state-dispute settlement (ISDS) give drug companies powerful tools to protect monopolies on medicines. An annex to the Transparency Chapter  risks negatively impacting access to medicines because of increased applicant access to medical product listing decisions...